Novo Nordisk Shares Surge 24.9% After Parkinson's AI Deal and Cell Therapy Exit
Novo Nordisk stock jumped 24.9% after the company closed its internal cell therapy unit and licensed its Parkinson's program to AI drug discovery firm Cellular Intelligence. The market is rewarding asset-light models that outsource early-stage risk to AI-native partners. NVIDIA's BioNeMo platform and a wave of specialized biological foundation models are cementing AI as biotech's core infrastructure layer.
Salvado•